A mesenchymal chondrosarcoma with aberrant nuclear expression of STAT6: a potential diagnostic pitfall.

Pathol Res Pract

Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy. Electronic address:

Published: April 2022

STAT6 is usually considered to be a very sensitive and specific immunomarker for diagnosis of solitary fibrous tumor (SFT), being a surrogate of the NAB2-STAT6 fusion gene identified in most cases of this tumor. STAT6 expression has also been reported in rare cases of other soft tissue tumors, such as low-grade fibromyxoid sarcoma, myxoid/round cell liposarcoma, dedifferentiated liposarcoma and deep fibrous histiocytoma. The aim of this study was to report, for the first time, a case of mesenchymal chondrosarcoma showing diffuse aberrant immunohistochemical expression of STAT6. Molecular biology, showing the HEY1-NCOA2 fusion gene, was crucial to rule out SFT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2022.153803DOI Listing

Publication Analysis

Top Keywords

mesenchymal chondrosarcoma
8
expression stat6
8
fusion gene
8
chondrosarcoma aberrant
4
aberrant nuclear
4
nuclear expression
4
stat6
4
stat6 potential
4
potential diagnostic
4
diagnostic pitfall
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!